The evolution into personalized therapies in pancreatic ductal adenocarcinoma: challenges and opportunities.

ABSTRACT:

Introduction

Pancreatic ductal adenocarcinoma (PDAC) is projected to be the second leading cause of cancer related mortality in the United States in 2030, with a 5-year overall survival of less than 10% despite decades of extensive research. Pancreatic cancer is marked by the accumulation of complex molecular changes, complex tumor-stroma interaction, and an immunosuppressive tumor microenvironment. PDAC has proven to be resistant to many cytotoxic, targeted and immunologic treatment approaches. Areas covered: In this paper, we review the major areas of research in PDAC, with highlights on the challenges and areas of opportunity for personalized treatment approaches. Expert commentary: The focus of research in pancreatic cancer has moved away from developing conventional cytotoxic

SUBMITTER: Tesfaye AA 

PROVIDER: S-EPMC6121777 | biostudies-literature | 2018 Feb

REPOSITORIES: biostudies-literature